ANX 042
Alternative Names: ANX042Latest Information Update: 24 Oct 2021
At a glance
- Originator Mayo Clinic
- Developer Anexon
- Class Heart failure therapies; Natriuretic peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Heart failure; Kidney disorders
Most Recent Events
- 01 Jan 2017 Mayo Clinic, National Institutes of Health and National Heart, Lung, and Blood Institute initiate the phase Ib ANX-042 Aim 1 trial for Heart failure and Kidney disorders in USA (IV, Infusion) (NCT03019653)
- 19 Apr 2016 No recent reports on development identified - Phase-I for Heart failure (In volunteers) in USA (IV)
- 19 Apr 2016 No recent reports on development identified - Phase-I for Kidney disorders (In volunteers) in USA (IV)